BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/29/2022 9:17:29 AM | Browse: 630 | Download: 1553
 |
Received |
|
2021-09-17 14:15 |
|
Peer-Review Started |
|
2021-09-17 14:16 |
|
First Decision by Editorial Office Director |
|
2021-12-09 07:41 |
|
Return for Revision |
|
2021-12-09 07:41 |
|
Revised |
|
2021-12-22 03:56 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-09-02 03:27 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-09-07 23:36 |
|
Articles in Press |
|
2022-09-07 23:36 |
|
Edit the Manuscript by Language Editor |
|
2022-08-19 07:29 |
|
Typeset the Manuscript |
|
2022-09-11 12:07 |
|
Publish the Manuscript Online |
|
2022-09-29 09:17 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhe Zhang and Chang-Qing Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chang-Qing Zheng, PhD, Doctor, Doctor, The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39, Huaxiang Road, Tiexi District, Shenyang, Shenyang 110004, Liaoning Province, China. zhengchangqing88@163.com |
| Key Words |
Immunotherapy; Colitis; Vedolizumab; Camrelizumab; Sintilimab; Case report |
| Core Tip |
With its good efficacy, immunotherapy is increasingly being used in treating malignant tumors and attention shall be paid to the immune-related side effects caused by this therapy. This is a report on Sintilimab and Carrelizumab induced colitis which has rarely been reported in the past. Besides, a positive effect was achieved by adopting Vedolizumab combined with short-term corticosteroids therapy, which was different from the previous treatment. |
| Publish Date |
2022-09-29 09:17 |
| Citation |
Zhang Z, Zheng CQ. Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World J Clin Cases 2022; 10(29): 10550-10558 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i29/10550.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i29.10550 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
